AU2001233156A1 - Bcl-2-like polynucleotides, polypeptides, and antibodies - Google Patents

Bcl-2-like polynucleotides, polypeptides, and antibodies

Info

Publication number
AU2001233156A1
AU2001233156A1 AU2001233156A AU3315601A AU2001233156A1 AU 2001233156 A1 AU2001233156 A1 AU 2001233156A1 AU 2001233156 A AU2001233156 A AU 2001233156A AU 3315601 A AU3315601 A AU 3315601A AU 2001233156 A1 AU2001233156 A1 AU 2001233156A1
Authority
AU
Australia
Prior art keywords
bcl
polynucleotides
polypeptides
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233156A
Inventor
D. Roxanne Duan
Jian Ni
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2001233156A1 publication Critical patent/AU2001233156A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2001233156A 2000-02-01 2001-01-31 Bcl-2-like polynucleotides, polypeptides, and antibodies Abandoned AU2001233156A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17948700P 2000-02-01 2000-02-01
US60179487 2000-02-01
US18069700P 2000-02-07 2000-02-07
US60180697 2000-02-07
PCT/US2001/003080 WO2001057060A1 (en) 2000-02-01 2001-01-31 Bcl-2-like polynucleotides, polypeptides, and antibodies

Publications (1)

Publication Number Publication Date
AU2001233156A1 true AU2001233156A1 (en) 2001-08-14

Family

ID=26875361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233156A Abandoned AU2001233156A1 (en) 2000-02-01 2001-01-31 Bcl-2-like polynucleotides, polypeptides, and antibodies

Country Status (6)

Country Link
US (1) US20020106731A1 (en)
EP (1) EP1257560A4 (en)
JP (1) JP2003523741A (en)
AU (1) AU2001233156A1 (en)
CA (1) CA2398255A1 (en)
WO (1) WO2001057060A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500587A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Screening and therapeutic methods relating to neurogenesis
US20090239793A1 (en) * 2004-09-24 2009-09-24 Isabella Caniggia Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover
NZ565683A (en) * 2005-07-08 2011-04-29 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
KR20080114689A (en) 2006-02-09 2008-12-31 유니버시티 오브 사우스 플로리다 Detection of cancer by elevated levels of bcl-2
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
PL2026803T3 (en) * 2006-05-16 2012-05-31 Knopp Neurosciences Inc Compositions of r(+) and s(-) pramipexole and methods of using the same
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CA2681110A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2408446B1 (en) 2009-03-20 2019-09-11 HG&H Pharmaceuticals (Pty) Limited Use of pharmaceutical compositions containing mesembrenone
AU2010224486B2 (en) 2009-03-20 2014-04-24 Hg&H Pharmaceuticals (Pty) Ltd Sceletium extract and uses thereof
EP2442655A4 (en) * 2009-06-19 2013-04-03 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015006708A1 (en) 2013-07-12 2015-01-15 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CA3105726A1 (en) * 2018-07-05 2020-01-09 Ovation Diagnostics Llc Bcl-2 antibodies and immunoassay for diagnosis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1306899A (en) * 1997-11-07 1999-05-31 Board Of Trustees Of The Leland Stanford Junior University Mammalian pro-apoptotic bok genes and their uses
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Also Published As

Publication number Publication date
EP1257560A1 (en) 2002-11-20
EP1257560A4 (en) 2003-10-01
US20020106731A1 (en) 2002-08-08
CA2398255A1 (en) 2001-08-09
JP2003523741A (en) 2003-08-12
WO2001057060A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001233156A1 (en) Bcl-2-like polynucleotides, polypeptides, and antibodies
AU2001271714A1 (en) B7-like polynucleotides, polypeptides, and antibodies
AU3075801A (en) Transferrin polynucleotides, polypeptides, and antibodies
AU1191001A (en) Plasminogen-like polynucleotides, polypeptides, and antibodies
AU2001253323A1 (en) Extracellular matrix polynucleotides, polypeptides, and antibodies
AU7337400A (en) B7-like polynucleotides, polypeptides, and antibodies
AUPQ976800A0 (en) Novel polypeptides and polynucleotides and uses therefor
AU1582401A (en) Uteroglobin-like polynucleotides, polypeptides, and antibodies
AU7335400A (en) Attractin-like polynucleotides, polypeptides, and antibodies
AU7330400A (en) Retinoid receptor interacting polynucleotides, polypeptides, and antibodies
AU2001241611A1 (en) Adam polynucleotides, polypeptides, and antibodies
AU2001238585A1 (en) Human polynucleotides, polypeptides, and antibodies
AU2002330672A1 (en) Gmg-1 polynucleotides and polypeptides and uses thereof
AU7056100A (en) Tgf-beta receptor polynucleotides, polypeptides, and antibodies
AU4001000A (en) Dwf4 polynucleotides, polypeptides and uses thereof
AU2590201A (en) Trefoil domain-containing polynucleotides, polypeptides, and antibodies
AU2001241610A1 (en) Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
AU2002351469A1 (en) Acrp30-like polynucleotides, polypeptides, and antibodies
AU4273099A (en) Polypeptides, polynucleotides and uses thereof
AU2050501A (en) Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
EP1212415A4 (en) Pgrp-l polynucleotides, polypeptides, and antibodies
AU2001229517A1 (en) Human polynucleotides, polypeptides, and antibodies
AU2001247306A1 (en) Immune system-related polynucleotides, polypeptides, and antibodies
IL161234A0 (en) Ngzipa, ngzipd, pgzipa and pgzipd polynucleotides and polypeptides and uses thereof
AU2001249898A1 (en) Tm4sf receptor polynucleotides, polypeptides, and antibodies